Rare diseases are genetically inherited and difficult to diagnose due to the availability of fewer treatment options. These diseases come under a heterogeneous group of diseases that can be characterized by a wide diversity of symptoms and affects a small percentage of the population. In addition to this, rare diseases are also called those diseases that are ignored or underappreciated by drug companies and the medical community. Misdiagnosis can lead to medical issues that could later be resulted in serious issues for the underlying disorder. Thus, it creates a need for timely and accurate diagnosis for rare conditions that drive significant demand for genetic testing.
全球罕见疾病的日益流行及其后果促进了对特殊治疗的需求，从而对全球罕见疾病治疗市场产生了积极影响。除此之外，罕见疾病癌症患者数量的不断增加、制药公司在制造诊断设备方面的努力不断增加、以及政府为加速研究活动提供的巨额资金，都是创造市场积极前景的关键因素。此外，全球人口对罕见疾病的认识不断提高，加上临床实践数据收集方面的快速技术进步，促进了市场的大幅增长。
- 这个molecular genetic tests segmentcontributed significant revenue share in the market, on account of rapid advancements in throughput technologies within healthcare settings, resulted in its increased adoption rate. Additionally, these test methods allow investigating short lengths of DNA that help to detect variations or mutations leading to genetic disorders.
- Accounting for major revenue share, theneurologic disorder segmentled the market and is expected to continue the progress in the same manner over the forecast period. The growing prevalence of rare ailments and the availability of genetic testing for neurologic conditions are driving the segmental growth.
- 研究实验室和CRO部门在罕见病基因检测市场上占有最大份额。疾病病例的大量增加和血液样本的采集被送往实验室进行检测是导致该段指数级增长的原因。
- Next-generation sequencing由于全外显子组测序的使用增加，预计将成为主要的收入贡献者。它被认为是在很难确定疾病遗传原因的情况下使用的高效和最快速的方法。
- 这个COVID-19 pandemic给全球的患者、研究人员和医疗保健专业人员带来了一些挑战。FDA正与生产商合作，开发出先进的治疗方法，以确保病人得到适当betway体育亚洲版入口的护理，并将重点放在常规临床试验上。
- 北美在预测期内，由于医疗支出的增加推动了该地区研究机构的发展，预计将成为最大的区域市场。越来越多的政府举措进一步促进了该地区的实质性增长。betway体育亚洲版入口
Ongoing research advances in healthcare have created lucrative opportunities for market players to develop solutions that can provide support in the management of rare conditions. Strategic collaborations are taken place among medical domains, scientific domains, and also various stakeholder groups such as patients, researchers, and regulators, thereby contributing to market growth. Arup Laboratories, Color Genomics, Inc., Health Network Laboratories, Opko Health, Inc., Centogene N.V., Invitae Corporation, Myriad Genetics, Inc., Perkin Elmer, Inc., Quest Diagnostics Inc., Coopersurgical, Inc., Strand Life Sciences, Eurofins Scientific, Fulgent Genetics Inc., and 3billion, Inc., are among the list of top players operating in the global rare disease genetic testing market.
Deep-dive Insights onRare Disease Genetic Testing Market by Polaris Market Research://m.jiayuancx.com/industry-analysis/rare-disease-genetic-testing-market